Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 1842 • 2016 ACR/ARHP Annual Meeting
Pentraxin 3 Level Positively Correlated with Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus Patients
Yifang Mei, Xiaoping Sun, Yuxia Shao, Huanhuan Zhan and Zhiyi Zhang, Department of Rheumatology, The First Affiliated Hospital of Harbin Medical University, Harbin, China
Background/Purpose: Systemic lupus erythematosus (SLE) is a kind of chronic and autoimmune disease with variable multi-system involvement of unknown causes, which is characterized by periods…
Abstract Number: 2791 • 2016 ACR/ARHP Annual Meeting
Targeting Micro-RNAs Derived from Extracellular Vesicles to Inhibit of TLR7 and TLR8 Signaling Suppresses Inflammation in a Novel Human-Mouse Chimeric Model of Systemic Lupus Erythematosus
Nicholas A. Young¹, Giancarlo R. Valiente², Holly Steigelman³, Jeffrey Hampton⁴ and Wael N. Jarjour⁵, ¹Immunology and Rheumatology, The Ohio State University Wexner Medical Center, Columbus, OH, ²Rheumatology & Immunology, The Ohio State University Wexner Medical Center, Columbus, OH, ³The Ohio State University, Columbus, OH, ⁴Immunology and Rheumatoloty, The Ohio State University Wexner Medical Center, Columbus, OH, ⁵Department of Rheumatology/Medicine, Ohio State University, Columbus, OH
Background/Purpose: Systemic lupus erythematosus (SLE) is a prototypic autoimmune disease displaying a heavy female predominance during reproductive years. We have previously shown that toll-like receptor…
Abstract Number: 2812 • 2016 ACR/ARHP Annual Meeting
Clinical Trial Simulation Identifies Factors for Patient Engagement in Systemic Lupus Erythematosus and Lupus Nephritis Trials By African-Americans
S. Sam Lim¹, Doug McKinnell², M Edward Pierson³ and Faye O'Brien³, ¹Medicine, Emory University School of Medicine, Atlanta, GA, ²Deloitte UK Life Sciences Advisory, London, United Kingdom, ³AstraZeneca, Gaithersburg, MD
Background/Purpose: Clinical trials of patients with systemic lupus erythematosus (SLE) and lupus nephritis (LN) can be confounded by difficulties in engaging patients. Identifying factors of…
Abstract Number: 2953 • 2015 ACR/ARHP Annual Meeting
The Emergency Room and SLE: What Characteristics Are Associated with Increased Emergency Room Utilization in Lupus Patients?
Kimberly Trotter¹, Kichul Ko¹, Gabrielle Liu¹ and Tammy Utset², ¹Medicine, University of Chicago, Chicago, IL, ²University of Chicago, Chicago, IL
Background/Purpose: There is sparse data examining the characteristics of SLE patients who frequent the emergency room (ER). Data suggest that lupus patients with certain sociodemographic…
Abstract Number: 3218 • 2015 ACR/ARHP Annual Meeting
A Randomized, Double-Blind, Placebo-Controlled, 52-Week Study of the Efficacy and Safety of Belimumab Administered Subcutaneously Plus Standard Care to Patients with Systemic Lupus Erythematosus (SLE)
William Stohl¹, Andreas Schwarting², Masato Okada³, Morton Scheinberg⁴, Andrea Doria⁵, Anne Hammer⁶, Christi Kleoudis⁷, Damon Bass⁸, James Groark⁹, Norma Lynn Fox¹⁰, David Roth¹¹ and David Gordon¹¹, ¹Division of Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, CA, ²ACURA Kliniken, Bad Kreuznach, Germany, ³Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan, ⁴Rheumatology Hospital Abreu Sodre Pesquisa Clínica, São Paulo, Brazil, ⁵Division of Rheumatology, University of Padova, Padova, Italy, ⁶GlaxoSmithKline, Research Triangle Park, NC, ⁷Parexel, Durham, NC, ⁸Immuno-Inflammation, GlaxoSmithKline, King of Prussia, PA, ⁹GlaxoSmithKline, Philadelphia, NC, ¹⁰GlaxoSmithKline, Washington, MD, ¹¹GlaxoSmithKline, Philadelphia, PA
Background/Purpose: To assess the efficacy and safety of belimumab (BEL) administered subcutaneously plus standard SLE care (SoC) in patients with active SLE.Methods: BLISS-SC (BEL112341; NCT01484496)…
Abstract Number: 737 • 2015 ACR/ARHP Annual Meeting
A Paper Patient-Based Flare Study in SLE
Joanna Sturgess¹, Elizabeth Allan¹, David A. Isenberg², Cynthia Aranow³, Martin Aringer⁴, Anca Askanase⁵, Sang-Cheol Bae⁶, Sasha R Bernatsky⁷, Ian N. Bruce⁸, Jill P. Buyon⁹, Ricard Cervera¹⁰, Ann Clarke¹¹, Mary Anne Dooley¹², Paul R. Fortin¹³, Ian Giles², Ellen M. Ginzler¹⁴, Dafna Gladman¹⁵, Caroline Gordon¹⁶, Bridget Griffiths¹⁷, John G. Hanly¹⁸, Murat Inanc¹⁹, Søren Jacobsen²⁰, Diane L. Kamen²¹, Munther Khamashta²², Peter Lanyon²³, S. Sam Lim²⁴, Susan Manzi²⁵, Marta Mosca²⁶, Ola Nived²⁷, Christine A. Peschken²⁸, Michelle Petri²⁹, Kenneth C. Kalunian³⁰, Anisur Rahman³¹, Rosalind Ramsey-Goldman³², Guillermo Ruiz-Irastorza³³, Jorge Sánchez-Guerrero³⁴, Matteus Schneider³⁵, Kristján Steinsson³⁶, Gunnar K. Sturfelt³⁷, Murray Urowitz^38,39, Ronald F. van Vollenhoven⁴⁰, Carlos Vasconcelos⁴¹, Daniel J Wallace⁴², Asad Zoma⁴³, Joan T. Merrill⁴⁴, Eric Morand⁴⁵, Sharon Chambers⁴⁶, Nathalie Costedoat-Chalumeau⁴⁷ and Sara Croca², ¹Statistics, London School of Hygiene and Tropical Medicine, London, United Kingdom, ²Rayne Institute, Centre for Rheumatology Research, UCL Division of Medicine, London, United Kingdom, ³Feinstein Institute for Medical Research, Mahasset, NY, ⁴Rheumatology, Universitatsklinikum, Dresden, Germany, ⁵Columbia University College of Physicians & Surgeons, New York, NY, ⁶Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ⁷Division of Rheumatolog, McGill Unversity Health Cener, Montreal, QC, Canada, ⁸Central Manchester University Hospital NHS Foundation Trust and Manchester Academic Health Science Centre, NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester, United Kingdom, ⁹Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ¹⁰Department of Autoimmune Diseases, Hospital Clínic, Barcelona, Spain, ¹¹Division of Rheumatology, Department of Medicine, University of Calgary, Calgary, AB, Canada, ¹²UNC Kidney Centre, Chapel Hill, NC, ¹³Université Laval, CHU de Québec, Québec, QC, Canada, ¹⁴Medicine/Box 42, SUNY-Downstate, Brooklyn, NY, ¹⁵Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ¹⁶Rheumatology (East Wing), Medical School, Birmingham, United Kingdom, ¹⁷Rheumatology, Freeman Hospital, Newcastle Upon Tyne, United Kingdom, ¹⁸Rheumatology, Division of Rheumatology, Capital Health and Dalhousie University, Halifax, NS, Canada, ¹⁹Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ²⁰Rheumatology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, ²¹Medicine, Medical University of South Carolina, Charleston, SC, ²²Graham Hughes Lupus Research Laboratory, The Rayne Institute, St Thomas' Hospital, London, United Kingdom, ²³Rheumatology, Queens Medical Centre Nottingham, Nottingham, United Kingdom, ²⁴Emory University School of Medicine, Atlanta, GA, ²⁵Rheumatology, Allegheny Health Network, Pittsburgh, PA, ²⁶University of Pisa, Pisa, Italy, ²⁷Rheumatology, Inst of Clinical sciences, Lund, Sweden, ²⁸Rheumatology, Univ of Manitoba, Winnipeg, MB, Canada, ²⁹Rheumatology, Johns Hopkins University Hospital, Baltimore, MD, ³⁰Division of Rheumatology, Allergy & Immunology, UCSD School of Medicine Center for Innovative Therapy, La Jolla, CA, ³¹Academic Centre for Rheumatology, University College London, London, United Kingdom, ³²Northwestern University Feinberg School of Medicine, Chicago, IL, ³³Universidad del Pais Vasco, Servicio de Medicina Interna, Hospital de Cruces, Bizkaia, Spain, ³⁴Rheumatology, Mount Sinai Hospital and University Health Network, Toronto Canada, Toronto, ON, Canada, ³⁵MNR-Klinik, Heinrich-Heine-Univ Dusseldorf, Dusseldorf, Germany, ³⁶Rheumatology, Univ. Hospital, Reykjavik, Iceland, ³⁷Department of Rheumatology, Univ Hospital Lund, Lund, Sweden, ³⁸University of Toronto, Toronto, ON, Canada, ³⁹Rheumatology, U of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴⁰Department of Medicine, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden, ⁴¹Medicina Interna, Unidade de Imunologia Clínica - Hospital Santo António, Oporto, Portugal, ⁴²Cedars-Sinai Medical Center, West Hollywood, CA, ⁴³Rheumatology, Hairmyres Hospital, East Kilbride, United Kingdom, ⁴⁴Clinical Pharmacology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴⁵Medicine, Monash University, Clayton, Australia, ⁴⁶TrinCay Medical Services, Camana Bay, Cayman Islands, ⁴⁷Internal Medicine Department, Cochin Hospital, “René-Descartes Paris V” University, Paris, France
ACR Abstract – A Paper Patient-Based Flare Study in Systemic Lupus Erythematosus (SLE) Isenberg D, Sturgess J, Allan E, Aranow C, Aringer M, Askanase A,…
Abstract Number: 747 • 2015 ACR/ARHP Annual Meeting
Depletion of Serum Soluble CD40L Characterizes the Association Between Systemic Lupus Erythematosus and Thrombotic Thrombocytopenic Purpura: Longitudinal, Single-Center Study
Javier Merayo-Chalico¹, Ana Barrera-Vargas², Jorge Alcocer-Varela² and Diana Gómez-Martín², ¹Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: Patients with systemic lupus erythematosus (SLE) have a higher incidence of thrombotic thrombocytopenic purpura (TTP). Differentiating TTP from SLE activity may represent a challenge…
Abstract Number: 780 • 2015 ACR/ARHP Annual Meeting
Long-Term Prognosis and Factors Associated with Damage Accrual in Japanese Patients with Systemic Lupus Erythematosus
Yoko Wada¹, Hisashi Hasegawa², Takeshi Kuroda³, Masaaki Nakano⁴ and Ichiei Narita¹, ¹Department of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan, ²Division of Clinical Nephrology and Rheumatology, Niigata City General Hospital, Niigata, Japan, ³Health Administration Center, Niigata University, Niigata, Japan, ⁴Department of Medical Technology, School of Health Sciences, Faculty of Medicine, Niigata University, Niigata, Japan
Background/Purpose: Systemic lupus erythematosus (SLE) is a multisystemic autoimmune disease characterized by fluctuating disease activity over periods of years. The estimated 5-year survival rate of…
Abstract Number: 1107 • 2015 ACR/ARHP Annual Meeting
Inhibition of B Cell Activation and Plasma Cell Differentiation By Epratuzumab, a Humanized Monoclonal Antibody Targeting CD22
Natalia V. Giltiay¹, Geraldine L. Shu², Anthony Shock³ and Edward A. Clark^1,2, ¹Division of Rheumatology, Department of Medicine, University of Washington, Seattle, WA, ²Department of Immunology, University of Washington, Seattle, WA, ³UCB Pharma, Slough, United Kingdom
Background/Purpose: Systemic lupus erythematosus (SLE) is characterized by B cell hyperactivity and production of autoantibodies. Treatment of patients with moderate-to-severe SLE with epratuzumab, a humanized…
Abstract Number: 2935 • 2015 ACR/ARHP Annual Meeting
Disease Evolution in Late Onset and Early Onset Systemic Lupus Erythematosus (SLE)
Roa'a Al Johani¹, Dafna Gladman², Jiandong Su² and Murray Urowitz^2,3, ¹Medicine, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Rheumatology, U of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: To compare clinical features, disease activity and outcome in late onset versus early onset SLE over 5 years of follow up. Methods: Patients with…
Abstract Number: 2647 • 2014 ACR/ARHP Annual Meeting
Predictors of Incident Seizure in Systemic Lupus Erythematosus
Xiangyang Huang¹, Laurence S. Magder² and Michelle Petri³, ¹Sichuan University School of Medicine, Sichuan, China, ²Department of Epidemiology and Public Health, University of Maryland, Baltimore, MD, ³Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: We identified the rate and risk factors for first occurrences of seizure based on a large closely followed longitudinal cohort of patients with systemic…
Abstract Number: 2622 • 2014 ACR/ARHP Annual Meeting
Systemic LUPUS Erythematosus in Spanish Males
Anne Riveros-Frutos¹, Irma Casas², Iñigo Rúa-Figueroa³, José Maria Pego-Reigosa⁴, M. Jesús García de Yebenes⁵, Alejandro Olivé⁶, Jose Rosas⁷, Paloma Vela⁸, Monica Ibanez Barcelo⁹, Vicente Torrente¹⁰, Ivan Castellvi¹¹, Javier Narváez¹², Mireia Moreno¹³, R. Blanco Alonso¹⁴, Víctor Martínez Taboada¹⁵, Jaime Calvo-Alen¹⁶, Mª Angeles Aguirre¹⁷, Mercedes Freire¹⁸, Enrique Raya¹⁹, Celia Erausquin²⁰, Esther Uriarte²¹, Elvira Díez Álvarez²², Tomás Vázquez Rodríguez²³, Antonio Fernández Nebro²⁴, Eva Tomero²⁵, Paloma García de la Peña²⁶, Ana Sánchez Atrio²⁷, Monica Fernández de Castro²⁸, Antonio Zea²⁹, Patricia Richi³⁰, Francisco Lopez Longo³¹, María Galindo-Izquierdo³², Patricia Carreira³³, Gema Bonilla³⁴, Carlos Marras Fernández Cid³⁵, Maria Loreto Horcada³⁶, Carlos Montilla³⁷, Blanca Hernández-Cruz³⁸, José Marenco de la Fuente³⁹, Marian Gantes⁴⁰, Olaia Fernández Berrizbeitia⁴¹, Juan J. Alegre⁴², Ángela Pecondón Español⁴³, Manuel Rodríguez-Gómez⁴⁴, Victor Quevedo⁴⁵, José Hernández Beiraín⁴⁶ and Lucía Silva Fernández⁴⁷, ¹Rheumatology, Hospital Universitario Germans Trias i Pujol, Badalona, Spain, ²Preventive Medicine, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, ³Rheumatology, Hospital Doctor Negrin, Las Palmas de Gran Canaria, Spain, ⁴Rheumatology, Hospital Meixoeiro, Vigo, Spain, ⁵Rheumatology, Research Unit of the SER, Madrid, Spain, ⁶Rheumatology, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, ⁷Rheumatology, Hospital Marina Baixa. Villajoyosa, Villajoyosa, Spain, ⁸Rheumatology, Hospital General de Alicante. Spain, Alicante, Spain, ⁹H. Son Llatzer, Palma de Mallorca, Spain, ¹⁰Rheumatology, Hospital Moisès Broggi, Barcelona, Spain, ¹¹Unitat de Reumatologia., Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ¹²Rheumatology, Hospital Universitario de Bellvitge. Barcelona. Spain, Barcelona, Spain, ¹³Rheumatology, Hospital Parc Taulí, Sabadell, Spain, ¹⁴Rheumatology, Hospital Universitario Marques de Valdecilla, Santander, Spain, ¹⁵Rheumatology, Marqués de Valdecilla, Santander, Spain, ¹⁶Rheumatology, Hospital de Sierrallana. Torrelavega. Spain, Torrelavega, Spain, ¹⁷Rheumatology, IMIBIC-Reina Sofia Hospital, Cordoba, Spain, ¹⁸Rheumatology, Hospital Universitario Juan Canalejo, La Coruña, Spain, ¹⁹Rheumatology, University Hospital San Cecilio, Granada, Spain, ²⁰Rheumatology, Hospital Dr, Negrín, Las Palmas Gran Canarias, Spain, ²¹Rheumatology, Hospital de Donosti, San Sebastian, Spain, ²²Rheumatology, Hospital de León. Spain, León, Spain, ²³Rheumatology, Hospital Lucus Augusti, Lugo, Spain, ²⁴Rheumatology, Hospital Carlos Haya. Malaga, Malaga, Spain, ²⁵Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, ²⁶Rheumatology, Hospital Norte Sanchinarro, Madrid, Spain, ²⁷Hospital Príncipe de Asturias, Immune System Diseases/Rheumatology department, Alcalá de Henares, Madrid, Spain, ²⁸Hospital Puerta del Hierro, Madrid, Spain, ²⁹Rheumatology, Hospital Universitario Ramon y Cajal, Madrid, Spain, ³⁰Hospital Infanta Sofía, Madrid, Spain, ³¹Rheumatology, Hospital Gregorio Marañón, Madrid, Spain, ³²Rheumatology, Hospital 12 de octubre, Madrid, Spain, ³³Rheumatology, Hospital Universitario 12 de Octubre, Madrid, Spain, ³⁴Rheumatology, Hospital La Paz, Madrid, Spain, ³⁵Hospital Virgen de la Arrixaca, Murcia, Spain, ³⁶Rheumatology, Complejo Hospitalario de Navarra, Pamplona, Spain, ³⁷Rheumatology, Hospital Clínico Universitario de Salamanca, Salamanca, Spain, ³⁸Rheumatology, University Hospital Virgen Macarena, Sevilla, Spain, ³⁹Rheumatology, Hospital de Valme, Sevilla, Spain, ⁴⁰Rheumatology, Hospital Universitario de Canarias, Tenerife, Spain, ⁴¹Rheumatology, Hospital de Basurto, Bilbao, Spain, ⁴²Rheumatology, Hospital Universitario Dr Peset, Valencia, Spain, ⁴³Rheumatology, Hospital Miguel Servet, Zaragoza, Spain, ⁴⁴Rheumatology, Complejo Hospitalario Universitario de Ourense, Ourense, Spain, ⁴⁵Rheumatology, Hospital de Monforte, Lugo, Spain, ⁴⁶Rheumatology, Hospital Insular de Gran Canaria, Las palmas Gran Canarias, Spain, ⁴⁷Rheumatology, Hospital Universitario de Guadalajara, Guadalajara, Spain

Background/Purpose: To describe the demographic, clinical and immunological manifestations in male patients with Systemic Lupus Erythematosus(SLE) Methods: Patients diagnosed of SLE that were in the…
Abstract Number: 1859 • 2014 ACR/ARHP Annual Meeting
Age-Specific Predictors of Mortality in SLE
Dominique Ibanez¹, Dafna D. Gladman² and Murray B. Urowitz², ¹Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Mortality is 3 to 5 times greater in SLE patients then it is in the general population – especially among younger patients where it…
Abstract Number: 1652 • 2014 ACR/ARHP Annual Meeting
Biomarkers of Lupus Nephritis and Ethnic Disparities in Systemic Lupus Erythematosus
Adnan Kiani¹, Laurence S. Magder² and Michelle Petri³, ¹1830 E Monument St, Johns Hopkins University School of Medicine, Baltimore, MD, ²Department of Epidemiology and Public Health, University of Maryland, Baltimore, MD, ³Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Lupus nephritis eventually occurs in 50% of Caucasian SLE patients and 75% of African-Americans. African Americans have a more severe presentation of SLE and…
Abstract Number: 1320 • 2014 ACR/ARHP Annual Meeting
Analysis of Risk Factors for Thrombosis in Pediatric Patients with Systemic Lupus Erythematosus
Kyla D. Driest¹, Mollie S. Sturm², Sarah H. O'Brien³, Charles H. Spencer⁴ and Stacy P. Ardoin⁵, ¹Rheumatology, OSU Pediatrics, Nationwide Children's Hospital, Columbus, OH, ²Nationwide Children's Hospital, Columbus, OH, ³Hematology, Nationwide Children's Hospital, Columbus, OH, ⁴Rheumatology, Nationwide Childrens Hospital, Columbus, OH, ⁵Pediatric & Adult Rheumatology, Ohio State University College of Medicine, Columbus, OH
Background/Purpose: Patients with systemic lupus erythematosus (SLE) have a higher thrombotic risk compared to the general population, and arterial and venous thromboses impart substantial morbidity…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].